A team of researchers has discovered a new set of epigenetic markers that may indicate whether a man is at risk of developing prostate cancer. The markers, which are changes in the way genes are expressed, were found in a group of men who went on to develop the disease.
The findings, published in the journal Nature Genetics, could lead to the development of a test that would help identify men at high risk of prostate cancer. The disease is the most common cancer in men, and the second leading cause of death from cancer in men.
Prostate cancer is often diagnosed at an early stage, when it is most treatable. However, the disease can be difficult to detect, and many men are not diagnosed until the cancer has spread.
The new epigenetic markers were found in a group of men who were followed for 15 years. The men were part of the Prostate Cancer Prevention Trial, which was designed to look at the effect of the drug finasteride on the development of prostate cancer.
The trial found that finasteride reduced the risk of developing prostate cancer by 24%. However, the drug also increased the risk of high-grade prostate cancer, which is more difficult to treat.
The researchers used a technique called “genome-wide DNA methylation profiling” to look for changes in the DNA of the men who developed cancer. They found that the men who went on to develop the disease had different patterns of DNA methylation than the men who did not develop cancer.
The researchers then looked for these DNA methylation patterns in a group of men who were not taking finasteride. They found that the men who had the same DNA methylation patterns as the men in the trial were more likely to develop prostate cancer.
The findings suggest that the DNA methylation patterns could be used to identify men at high risk of prostate cancer. The researchers say that further studies are needed to confirm the findings.
If the findings are confirmed, the DNA methylation patterns could be used to develop a test that would help identify men at high risk of prostate cancer. The test could be used to help select men for prostate cancer screening and to guide decisions about treatment.
A new study has found epigenetic markers that could be used to better diagnose and treat prostate cancer.
In the study, researchers looked at a group of men with prostate cancer and compared their epigenetic profiles to those of healthy men. They found several epigenetic markers that were different between the two groups.
“These epigenetic markers could be used to improve prostate cancer diagnosis and treatment,” said study senior author Dr. Luisa M. Petricoin, of George Mason University. “They could also be used to monitor the disease and predict how it will progress.”
The study was small, and more research is needed to confirm the findings. But the findings could lead to new ways to diagnose and treat prostate cancer, which is the most common cancer in men.
Prostate cancer is often diagnosed at an early stage, when it is still treatable. But it can be difficult to diagnose, because there are no symptoms in the early stages.
The study was published in the journal Nature Medicine.